Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab

Toxicology and Applied Pharmacology

Volumn 138, Issue 1, 1996, Pages 84-89

  Grene Lerouge, N A M ^a   Bazin Redureau, M I ^a   Debray, M ^b   Scherrmann, J M G ^a  

^a HÔPITAL FERNAND WIDAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN ANTIBODY F(AB) FRAGMENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; RABBIT; RADIOIMMUNOASSAY; RAT; SPECIES DIFFERENCE;

ANIMALIA; MAMMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0029951502     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.0101     Document Type: Article

References (19)

1. Allen, N. M., Dunham, G. D., Sailstad, J. M., and Findlay, J. W. A. (1991). Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment. DICP 25, 1315-1320.
2. Arend, W. P., and Silverblatt, F. J. (1975). Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. Clin. Exp. Immunol. 22, 502-513.
3. Boxenbaum, H. (1982). Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10(2), 201-227.
4. Boxenbaum, H. (1984). Interspecies pharmacokinetic scaling and the evolutionary comparative paradigm. Drug Metab. Rev. 15(5/6), 1071-1121.
5. Boxenbaum, H., and Ronfeld, R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. 245, R768-R775.
6. Dedrick, R. L., Bischoff, K. B., and Zaharko, D. Z. (1970). Interspecies correlation of plasma concentration history of Methotrexate (NSC-740). Cancer Chemother. Rep. Part 1 54, 95-101.
7. Fraker, P. J., and Speck, J. C. (1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetra-chloro-3α-6α-diphenylglycoluril. Biochem. Res. Commun. 80, 849-857.
8. Gibaldi, M., and Perrier, D. (1982). In Pharmacokinetics (M. Gibaldi and D. Perrier, Eds.), pp. 199-219, 410. Dekker, New York.
9. Ings, R. M. J. Interspecies scaling and comparisons in drug development and toxicokinetics. (1990). Xenobiotica 20(11), 1201-1231.
10. Mordenti, J. (1985). Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data. J. Pharm. Sci. 74(10), 1097-1099.
11. Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B. L., and Green, J. G. (1991). Interspecies scaling of clearance and volume of distribution dara for five therapeutics proteins. Pharm. Res. 8(11), 1351-1359.
12. Mordenti, J., and Green, J. D. (1991). The role of pharmacokinetics and pharmacodynamics in the development of therapeutic proteins. In New Trends in Pharmacokinetics (A. Rescigno and A. K. Thakur, Eds.), NATO ASI Series, pp. 411-424. Plenum, New York.
13. Sabouraud, A., Urtizberea, M., Benmoussa, K., Cano, N., and Scherrmann, J. M. (1992). Fab-bound colchicine appears to adopt Fab fragment disposition in rats. J. Pharm. Pharmacol. 44, 1015-1019.
14. Schaumann, W., Kaufmann, B., Neubert, P., and Smolarz, A. (1986). Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur. J. Clin. Pharmacol. 30, 527-533.
15. Sinclair, A. J., Hewick, D. S., Johnston, P. C., Stevenson, I. H., and Lemon, M. (1989). Kinetics of digoxin and antibody fragments during treatment of digoxin toxicity. Br. J. Clin. Pharmacol. 28, 352-356.
16. Smith, T. W., Butler, V. P., Haber, E., Fozzard, H., Marcus, F. I., Bremner, W. F., Schulman, I. C., and Philipps, A. (1982). Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. N. Engl. J. Med. 307, 1357-1362.
17. Smith, T. W., Haber, E., Yeatman, L., and Butler, V. P. (1976). Reversal of advanced digoxin intoxication with Fab-fragments of digoxin specific antibodies. N. Engl. J. Med. 294, 797-800.
18. Ujhelyi, M. R., Robert, S., Cummings, D. M., Colucci, R. D., Sailstad, J. M., Vlasses, P. H., Findlay, J. W. A., and Karowitz, B. J. (1993). Disposition of digoxin immune Fab in patients with kidney failure. Clin. Pharmacol. Ther. 54, 388-394.
19. Vo Thanh-Barthet, C., Urtizberea, M., Sabouraud, A. E., Cano, N. J., and Scherrmann, J. M. (1993). Development of a sensitive radioimmunoassay for Fab fragments: Application to Fab pharmacokinetics in humans. Pharm. Res. 10(5), 692-696.